SMT202200169T1 - Composti a base di morfolinilpiridone - Google Patents

Composti a base di morfolinilpiridone

Info

Publication number
SMT202200169T1
SMT202200169T1 SM20220169T SMT202200169T SMT202200169T1 SM T202200169 T1 SMT202200169 T1 SM T202200169T1 SM 20220169 T SM20220169 T SM 20220169T SM T202200169 T SMT202200169 T SM T202200169T SM T202200169 T1 SMT202200169 T1 SM T202200169T1
Authority
SM
San Marino
Prior art keywords
morpholinylpyridone
compounds
morpholinylpyridone compounds
Prior art date
Application number
SM20220169T
Other languages
English (en)
Italian (it)
Inventor
Johan Lindström
Rickard Forsblom
Jenny Viklund
Original Assignee
Sprint Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab
Publication of SMT202200169T1 publication Critical patent/SMT202200169T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20220169T 2017-08-23 2018-08-23 Composti a base di morfolinilpiridone SMT202200169T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS
EP18759105.2A EP3672962B1 (en) 2017-08-23 2018-08-23 Morpholinylpyridone compounds

Publications (1)

Publication Number Publication Date
SMT202200169T1 true SMT202200169T1 (it) 2022-05-12

Family

ID=59686888

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220169T SMT202200169T1 (it) 2017-08-23 2018-08-23 Composti a base di morfolinilpiridone

Country Status (20)

Country Link
US (2) US11560374B2 (enExample)
EP (2) EP4056569A1 (enExample)
JP (2) JP7199736B2 (enExample)
KR (1) KR102732013B1 (enExample)
CN (3) CN116462674A (enExample)
AU (2) AU2018320419B2 (enExample)
CY (1) CY1125117T1 (enExample)
DK (1) DK3672962T3 (enExample)
ES (1) ES2910157T3 (enExample)
HR (1) HRP20220497T1 (enExample)
HU (1) HUE058661T2 (enExample)
IL (3) IL302077A (enExample)
LT (1) LT3672962T (enExample)
PL (1) PL3672962T3 (enExample)
PT (1) PT3672962T (enExample)
RS (1) RS63109B1 (enExample)
SI (1) SI3672962T1 (enExample)
SM (1) SMT202200169T1 (enExample)
TW (2) TW202348601A (enExample)
WO (1) WO2019038390A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022115558A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
JP2023550638A (ja) 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ,エルエルシー ウイルス感染症の処置に使用するための、vsp34阻害剤としてのモルホリノ誘導体
EP4251156A1 (en) * 2020-11-25 2023-10-04 Deciphera Pharmaceuticals, LLC Anti-viral activity of vps34 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1805142A4 (en) * 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
EA201390917A1 (ru) 2010-12-21 2013-12-30 Новартис Аг Дигетероарильные соединения в качестве ингибиторов vps34
PT2655375E (pt) 2010-12-23 2015-03-02 Sanofi Sa Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
JP6074043B2 (ja) * 2013-08-29 2017-02-01 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
PL3416945T3 (pl) 2016-02-19 2020-12-28 Sprint Bioscience Ab Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy
PT3416957T (pt) 2016-02-19 2020-09-25 Sprint Bioscience Ab Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes

Also Published As

Publication number Publication date
JP7199736B2 (ja) 2023-01-06
LT3672962T (lt) 2022-05-10
CN116462674A (zh) 2023-07-21
TW202348601A (zh) 2023-12-16
IL292489A (en) 2022-06-01
PL3672962T3 (pl) 2022-05-02
HRP20220497T1 (hr) 2022-05-27
US20200361922A1 (en) 2020-11-19
EP3672962A1 (en) 2020-07-01
WO2019038390A1 (en) 2019-02-28
AU2018320419B2 (en) 2023-09-28
JP2020531485A (ja) 2020-11-05
IL302077A (en) 2023-06-01
RU2020110506A (ru) 2021-09-23
CN111108102A (zh) 2020-05-05
CN111108102B (zh) 2023-04-28
US11560374B2 (en) 2023-01-24
EP3672962B1 (en) 2022-01-26
AU2023285995A1 (en) 2024-01-25
IL272815B (en) 2022-06-01
EP4056569A1 (en) 2022-09-14
KR20200044025A (ko) 2020-04-28
RS63109B1 (sr) 2022-04-29
PT3672962T (pt) 2022-04-12
HUE058661T2 (hu) 2022-09-28
ES2910157T3 (es) 2022-05-11
JP2023021268A (ja) 2023-02-10
SI3672962T1 (sl) 2022-06-30
IL292489B1 (en) 2023-05-01
TW201912161A (zh) 2019-04-01
CN116444510A (zh) 2023-07-18
US20230234949A1 (en) 2023-07-27
DK3672962T3 (da) 2022-05-02
KR102732013B1 (ko) 2024-11-18
AU2018320419A1 (en) 2020-04-09
IL272815A (en) 2020-04-30
IL292489B2 (en) 2023-09-01
CA3073142A1 (en) 2019-02-28
CY1125117T1 (el) 2024-12-13
TWI803511B (zh) 2023-06-01
RU2020110506A3 (enExample) 2022-02-22

Similar Documents

Publication Publication Date Title
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
IL292489B1 (en) Morpholinylpyridone compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201720064D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds
GB201716688D0 (en) Compounds
GB201716374D0 (en) Compounds
GB201716352D0 (en) Compounds